The DJS Law Group, a firm focused on shareholder rights litigation, is notifying investors about a class action lawsuit filed against Pinterest, Inc. (“Pinterest” or “the Company”) (NYSE: PINS). The case alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5 issued by the U.S. Securities and Exchange Commission.

Investors who acquired PINS shares during the specified class period may reach out to the firm to learn about seeking appointment as lead plaintiff. Serving as lead plaintiff is optional and not necessary to be eligible for any potential recovery.

Class Period: February 7, 2025 to February 12, 2026
Lead Plaintiff Deadline: May 29, 2026

Case Summary: According to the complaint, Pinterest allegedly issued statements that were inaccurate and misleading. The company reportedly faced declining advertising revenue from partners and provided investors with an overly optimistic view of its ability to navigate U.S. tariff challenges. As a result, it is claimed that the company’s public disclosures during the class period were materially false or misleading.

Shareholders who experienced financial losses are encouraged to get in touch to explore participation in the case.

About DJS Law Group: The firm focuses on maximizing investor recoveries through strategic guidance and assertive representation. Its practice areas include securities class actions, corporate governance disputes, and domestic as well as international merger and acquisition appraisals. The firm represents a range of prominent hedge funds and alternative asset managers, handling high-value litigation matters with a results-driven approach.

Potential claimants are invited to join the action to pursue compensation for their losses.

This announcement may qualify as attorney advertising under applicable laws and ethical rules in certain jurisdictions.

Contact Information:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com

• The Phase 3 clinical trials for DCCR—its sole commercial product intended to treat hyperphagia in individuals with Prader-Willi syndrome (PWS)—allegedly downplayed, misrepresented, or omitted significant evidence of safety concerns, including signs of excessive fluid retention in participants.
• As a result, the treatment may have posed greater safety risks than what the company disclosed publicly.
• Consequently, DCCR’s commercial prospects were potentially overstated, while risks such as adverse side effects, higher discontinuation rates, reduced patient uptake, physician hesitation, possible regulatory challenges, and reputational or legal consequences were not fully revealed.